Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Background/AimsSilibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells.MethodsSeve...

Full description

Bibliographic Details
Main Authors: Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2015-03-01
Series:Clinical and Molecular Hepatology
Subjects:
Silibinin
Gefitinib
Sorafenib
Hepatocellular carcinoma
Online Access:http://e-cmh.org/upload/pdf/cmh-21-49.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-21-49.pdf

Similar Items